| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.04 | 0.5 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.5 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.21 | 0.5 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.093 | 0.5 |
| mRNA | Panobinostat | FIMM | pan-cancer | AAC | 0.1 | 0.5 |